Brief: Mesoblast Says FDA Grants Orphan Drug Designation For Revascor
15/02/2024 01:26
Feb 15 (Reuters) - Mesoblast Ltd MSB.AX :
* FDA GRANTS ORPHAN DRUG DESIGNATION FOR REVASCOR
Source text for Eikon: ID:nASX5L51Ry
Further company coverage: MSB.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mesoblast
See all newsBrief: Mesoblast Reports QTRLY Ryoncil Net Revenues Of $30.3 Million
ASX-shares of Mesoblast rise after back-treatment drug hits patent target
Australia's Mesoblast soars on bagging licence for Mayo Clinic-developed tech
Brief: Mesoblast Acquires CAR Platform For Precision-Enhanced Cell Products
Brief: Mesoblast Says Ryoncil's Net Revenue For Quarter Increases To US$30.3M